# GLP-1 Therapy: Cardiometabolic Benefit With Nutritional Vigilance

Different agents and populations have different outcome evidence. Confirm the actual paper before quoting a kidney endpoint or applying one study to every class member.

![Infographic: GLP-1 Therapy: Cardiometabolic Benefit With Nutritional Vigilance](https://urinenephrology.org/visual-reference/images/mastery-glp1.png?v=20261003c)

## Multiple pathways

GLP-1 receptor agonists affect glucose regulation, appetite, weight, and cardiometabolic risk. Kidney effects must be interpreted within the specific trial and clinical population.

## Define the treatment goal

Consider glycemic control, obesity-related burden, cardiovascular risk, and CKD alongside patient priorities and tolerability.

## Recognize intolerance that changes treatment

Persistent vomiting, reduced intake, orthostasis, or falling urine output should prompt assessment for dehydration and medication-related AKI. Review diuretics and other interacting illness risks. Monitor weight alongside muscle strength and food intake so loss of lean tissue is not counted as an uncomplicated success.

## Follow beyond body weight

Monitor hydration, kidney function when clinically indicated, nutritional intake, strength, and functional capacity. Weight loss is not always equivalent to improved health.

## Coordinate care

Dietary support, activity suited to the patient, and medication review can help preserve function during treatment. Acute illness and procedures may require specific advice.

## Apply the actual kidney-outcome evidence

FLOW tested semaglutide in people with type 2 diabetes and CKD. Do not generalize its kidney outcome automatically to every GLP-1 agent, people without diabetes, or dialysis. Select treatment for the person’s indication and assess gastrointestinal tolerance, hypoglycemia risk with co-therapy, and nutrition.

## Source lessons

- [glp1 guide](https://urinenephrology.org/mastery/cardiorenal/glp1-guide.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.